Wegovy News

Lilly's obesity pill draws 1,390 US prescriptions in launch week - Reuters

Lilly's obesity pill draws 1,390 US prescriptions in launch week Reuters

Novo Nordisk Launches Wegovy Subscription Program - Medscape

Novo Nordisk Launches Wegovy Subscription Program Medscape

Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch - BioSpace

Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch BioSpace

What Is 'Eye Stroke'? Expert Explains The Rare Wegovy Risk - ScienceAlert

What Is 'Eye Stroke'? Expert Explains The Rare Wegovy Risk ScienceAlert

Ozempic Is About to Go Generic for Billions of People - The New York Times

Ozempic Is About to Go Generic for Billions of People The New York Times

The FDA approves a new obesity pill, giving patients another option - NPR

The FDA approves a new obesity pill, giving patients another option NPR

Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S. - WSJ

Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S. WSJ

Patients regain weight rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost - University of Cambridge

Patients regain weight rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost University of Cambridge

Weight-loss jabs will be offered on NHS for people at risk of further heart attacks - BBC

Weight-loss jabs will be offered on NHS for people at risk of further heart attacks BBC

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison - CNBC

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison CNBC

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development - Reuters

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development Reuters

Zepbound leads to greater weight loss — and muscle loss — than Wegovy: study - FirstWord Pharma

Zepbound leads to greater weight loss — and muscle loss — than Wegovy: study FirstWord Pharma

Colorado Senate passes bill to regulate compounded weight loss drugs - CBS News

Colorado Senate passes bill to regulate compounded weight loss drugs CBS News

Novo Nordisk’s Wegovy Wins EMA Flexibility In GLP-1 Access Push - Yahoo Finance

Novo Nordisk’s Wegovy Wins EMA Flexibility In GLP-1 Access Push Yahoo Finance

Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity - VCU Health

Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity VCU Health

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it - NPR

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it NPR

Novo Nordisk's Wegovy® HD available now nationwide - PR Newswire

Novo Nordisk's Wegovy® HD available now nationwide PR Newswire

Comparison of Oral Semaglutide (Wegovy) and Orforglipron (Foundayo) for the Treatment of Obesity and Overweight - Medical Professionals Reference

Comparison of Oral Semaglutide (Wegovy) and Orforglipron (Foundayo) for the Treatment of Obesity and Overweight Medical Professionals Reference

EXCLUSIVE: New Subscription Program for Wegovy Could Save Patients $1,200 a Year — How to Access It - TODAY.com

EXCLUSIVE: New Subscription Program for Wegovy Could Save Patients $1,200 a Year — How to Access It TODAY.com

How do weight-loss drugs like Mounjaro and Wegovy work? - BBC

How do weight-loss drugs like Mounjaro and Wegovy work? BBC

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. - Investor's Business Daily

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. Investor's Business Daily

Wegovy Launches New Subscription—How to Save Up to $1,200 - Forbes

Wegovy Launches New Subscription—How to Save Up to $1,200 Forbes

FDA Approves Higher-Dose Wegovy To Help People Lose More Weight - Infectious Disease Advisor

FDA Approves Higher-Dose Wegovy To Help People Lose More Weight Infectious Disease Advisor

GLP-1 Weight-Loss Pills: What You Need to Know - Yale Medicine

GLP-1 Weight-Loss Pills: What You Need to Know Yale Medicine

GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month - Fierce Healthcare

GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month Fierce Healthcare

Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity - GOV.UK

Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity GOV.UK

Ozempic, Wegovy: Why GLP-1 Drugs Don't Work for Everyone - Healthline

Ozempic, Wegovy: Why GLP-1 Drugs Don't Work for Everyone Healthline

Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery - WSJ

Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery WSJ

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year - PR Newswire

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year PR Newswire

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds - Reuters

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds Reuters

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment - CNBC

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment CNBC

Weight loss: What to do if GLP-1s like Wegovy alone aren't working - Medical News Today

Weight loss: What to do if GLP-1s like Wegovy alone aren't working Medical News Today

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 - PR Newswire

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 PR Newswire